ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Lawrence S. Honig(Columbia University), Marwan Sabbagh(Banner Sun Health Research Institute), Larisa Reyderman(Eisai (United States)), Chad J. Swanson(Eisai (United States)), Jerome Barakos(Sutter Health), Michael C. Irizarry(Eisai (United States)), Michio Kanekiyo(Eisai (United States)), Lynn D. Kramer(Eisai (United States)), Shobha Dhadda(Eisai (United States))
Alzheimer s & Dementia Translational Research & Clinical Interventions
January 1, 2023
Cited by 108
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
|The Lancet Neurology|2013|3.1k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
|Nature Neuroscience|1999|938